AU5331499A - Indole spla2 inhibitors - Google Patents

Indole spla2 inhibitors

Info

Publication number
AU5331499A
AU5331499A AU53314/99A AU5331499A AU5331499A AU 5331499 A AU5331499 A AU 5331499A AU 53314/99 A AU53314/99 A AU 53314/99A AU 5331499 A AU5331499 A AU 5331499A AU 5331499 A AU5331499 A AU 5331499A
Authority
AU
Australia
Prior art keywords
spla2 inhibitors
indole spla2
indole
inhibitors
spla2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU53314/99A
Other languages
English (en)
Inventor
Edward David Mihelich
Michael Leroy Phillips
Alan M. Warshawsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU5331499A publication Critical patent/AU5331499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AU53314/99A 1998-08-03 1999-08-02 Indole spla2 inhibitors Abandoned AU5331499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9510998P 1998-08-03 1998-08-03
US60095109 1998-08-03
PCT/US1999/017460 WO2000007591A1 (en) 1998-08-03 1999-08-02 INDOLE sPLA2 INHIBITORS

Publications (1)

Publication Number Publication Date
AU5331499A true AU5331499A (en) 2000-02-28

Family

ID=22249729

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53314/99A Abandoned AU5331499A (en) 1998-08-03 1999-08-02 Indole spla2 inhibitors

Country Status (6)

Country Link
US (2) US6608099B1 (enExample)
EP (1) EP1100493A4 (enExample)
JP (1) JP2002522386A (enExample)
AU (1) AU5331499A (enExample)
CA (1) CA2338727A1 (enExample)
WO (1) WO2000007591A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100493A4 (en) * 1998-08-03 2001-10-24 Lilly Co Eli SPLA 2 INHIBITORS? OF THE INDOLTYPS
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
AU2001232734A1 (en) * 2000-03-09 2001-09-17 Eli Lilly And Company Compositions containing potential spla2 inhibitors for the treatment of pain
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
DE60208065T2 (de) 2001-08-09 2006-07-13 Eli Lilly And Co., Indianapolis Cyclohept'b! indolderivate als spla2-inhibitoren
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
EP1479677A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
WO2005107767A2 (en) * 2004-05-03 2005-11-17 Ilypsa, Inc. Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
WO2007056279A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
AU2006311851A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-A2 inhibitors
JP2009517341A (ja) * 2005-11-03 2009-04-30 イリプサ， インコーポレイテッド Ｃ４−アミド置換基を有するインドール化合物およびホスホリパーゼａ２インヒビターとしてのその使用
WO2007056280A1 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors
WO2007056281A2 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
ATE220394T1 (de) 1994-04-01 2002-07-15 Lilly Co Eli 1h-indol-3-glyoxylamid spla2 inhibitoren
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
CA2338855A1 (en) * 1998-08-03 2000-02-17 Eli Lilly And Company Indole spla2 inhibitors
EP1100493A4 (en) * 1998-08-03 2001-10-24 Lilly Co Eli SPLA 2 INHIBITORS? OF THE INDOLTYPS

Also Published As

Publication number Publication date
US7026348B2 (en) 2006-04-11
US20030191175A1 (en) 2003-10-09
JP2002522386A (ja) 2002-07-23
EP1100493A1 (en) 2001-05-23
WO2000007591A1 (en) 2000-02-17
EP1100493A4 (en) 2001-10-24
CA2338727A1 (en) 2000-02-17
US6608099B1 (en) 2003-08-19

Similar Documents

Publication Publication Date Title
AU8030598A (en) Indole compounds as cox-2 inhibitors
AU3140695A (en) 1h-indole-1-functional spla2 inhibitors
AU2001274009A1 (en) Substituted indoles as parp inhibitors
IL138387A0 (en) Enzyme inhibitors
AU6229699A (en) Beta-amyloid formation inhibitors
AU5633300A (en) Indole compounds
AU5331499A (en) Indole spla2 inhibitors
AU2723099A (en) Tryptase inhibitors
AU3703499A (en) Substituted indolinones as kinase inhibitors
AU5589298A (en) Phenyl acetamides as spla2 inhibitors
GB9825988D0 (en) Indole derivatives
AU4685799A (en) Telomerase inhibitors
AU7125700A (en) Enzyme inhibitors
AU7450898A (en) Indole compounds
AU1393900A (en) Morpholino-ethoxybenzofuran protease inhibitors
AU2373600A (en) Novel spla2 inhibitors
AU3235100A (en) Prothease inhibitors
GB9924522D0 (en) Enzyme inhibitors
GB9816358D0 (en) Enzyme inhibitors
AU2849399A (en) Monobactam enzyme inhibitors
AU1149797A (en) Naphthyl glyoxamides as spla2 inhibitors
AU1279899A (en) N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
PL343708A1 (en) Spla2
AU7127000A (en) Enzyme inhibitors
AU2713399A (en) 5-heteroaryl substituted indoles

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase